PARP1 and cancer: Recently, a phase I study investigating different schedules for the combination of irinotecan and the PARP inhibitor rucaparib in refractory cancers bearing mutations in HRR genes was presented, showing how pulse schedules are clinically feasible and that the patient population with ATM-mutated cancers exhibits the greatest benefit from the combination [41].